about
New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccinationInter-allelic recombination in the Plasmodium vivax merozoite surface protein 1 gene among Indian and Colombian isolatesStructure, Immunogenicity, and Protectivity Relationship for the 1585 Malarial Peptide and Its Substitution AnaloguesStage-dependent localization of a novel gene product of the malaria parasite, Plasmodium falciparumAdvocacy, promotion and e-learning: Supercourse for zoonosisThe challenge of emerging and re-emerging infectious diseasesThe chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferencesInduction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1Onset of clinical immunity to Plasmodium falciparum among Javanese migrants to Indonesian Papua.Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adultsThe dichotomy (generation of MAbs with functional heterogeneity) in antimalarial immune response in vaccinated/protected mice: a new concept in our understanding of the protective immune mechanisms in malaria.Tropical medicine.Genetics of mosquito vector competence.posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.Current status of malaria and potential for control.CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.Human resistance to Plasmodium falciparum increases during puberty and is predicted by dehydroepiandrosterone sulfate levels.Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains.Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice.Specificity of the protective antibody response to apical membrane antigen 1Development of vaccines against human parasitic diseases: tools, current status and perspectives.The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodiesBiochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccinePassive immunization with a multicomponent vaccine against conserved domains of apical membrane antigen 1 and 235-kilodalton rhoptry proteins protects mice against Plasmodium yoelii blood-stage challenge infection.A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.Exoerythrocytic malaria vaccine development: understanding host-parasite immunobiology underscores strategic success.Vaccine strategies for infectious diseases.Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune responseThe potential impact of integrated malaria transmission control on entomologic inoculation rate in highly endemic areas.Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.HLA-A*01-restricted cytotoxic T-lymphocyte epitope from the Plasmodium falciparum circumsporozoite protein.Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin.Transdermal immunization of P. falciparum surface antigen (MSP-119) via elastic liposomes confers robust immunogenicity.Malaria vaccines-targeting infected hepatocytes.Initiating malaria control programs in the third world: directives for short- and long-term solutions.Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
P2860
Q24800305-8D7D957A-F166-404D-B4BF-CF87927E67C2Q24804056-8CDD9058-EB66-4155-BF85-C55872DEA00CQ27639886-0CEAC7C4-B71A-4C50-9C5D-4F3A7148A278Q27972741-7DAA9E3E-63F6-4EE4-9B5E-92F8AF4617E6Q28390170-83DBDA85-0E85-4AFD-A444-98186B7ABEE6Q29617354-B107B6A9-1710-4CD5-8540-98A14F8C709CQ30041470-74253C60-E99F-46B1-81A3-5E53D447C83BQ30967137-53A1092B-41A1-4601-9B0A-E75D784442CFQ31002453-362680DB-DB2A-4BA8-B154-78AD542A3472Q33380213-3E543834-6DBC-4DFE-9CE6-15D35EB861CCQ33577949-F0620ACF-4B53-4073-B4D8-CD71A034D6FAQ33817432-AAAFEFF1-8833-4B2B-8A73-6AD683F63B0BQ33855250-57F81140-4FE7-4D2A-A698-04C0C02FD2AFQ33883252-2DAD1BA2-34F1-4ABE-A364-A9B2E0F30B2AQ33897645-C6AD405E-0F08-45A0-83D8-6F870BA20D36Q33975652-628E9856-4DFD-49D9-B7D9-37872F47AC13Q34002308-2000F91F-7CB6-4DF2-BBE4-EDE31F893046Q34005512-A1B908E2-0274-4549-B4FD-E3354BEDB811Q34006127-0A863945-C27A-4AC7-8317-C2A44D245141Q34006332-0C37C98C-1C1B-4DC9-8342-270CB01F24C4Q34006411-83DD8FEE-3BE6-4686-9A2F-B70375460DCDQ34007362-0361A0A6-3B77-431E-BBCD-89BB9F0B7224Q34074704-CFBE32DF-D6D1-4765-ABEB-AF43ED3BDEEFQ34131183-F6A405DD-B88F-44B8-B9C0-F8D918DDFA45Q34940333-810984AB-A8CA-40C8-8D50-C70F554F4DD2Q34975629-C9707E05-6D8A-4CD0-B306-2229DE0800FDQ35005868-A6645DD8-AE53-49D0-AD2C-D9017923BE96Q35073867-A806925E-8BF0-4547-A8A9-2215A1DCADA5Q35122498-4F4C566C-17FD-448F-A2C0-469A6A242696Q35193463-82B92637-D2D3-4D69-93BD-1ACA5311181AQ36181264-AC1AE9A1-4390-4522-9A21-BFBCA5400AC2Q36446656-1B216EFE-CF71-438E-9FE3-DF543A7A7E37Q36818112-5BB43028-7F4A-449F-B1BA-B568D321644EQ37523989-9C7FC976-D033-4E27-9A6C-F21322D0FF87Q39519692-FC57EF42-EEB6-49EB-BC0E-050B3EBE5389Q41912941-D51EA088-5651-40E5-AF4A-05883A0A8268Q42157286-C3B9FAD5-FB33-4FFA-B8B8-A4C93DF8EA48Q44144359-9AA7486E-F71E-44F6-851B-A19A1D8243B3Q44148848-33BB65E0-AFA6-4CF1-A1EF-B71FE6690869Q45749788-03F43448-5F3B-4695-BCAA-95C2D7973F80
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Research toward vaccines against malaria.
@en
type
label
Research toward vaccines against malaria.
@en
prefLabel
Research toward vaccines against malaria.
@en
P2860
P356
P1433
P1476
Research toward vaccines against malaria.
@en
P2860
P2888
P304
P356
10.1038/NM0598SUPP-520
P407
P433
P577
1998-05-01T00:00:00Z